The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,262% of patients treated with ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...

ITP is an autoimmune condition where the body’s immune cells mistakenly attack platelets, the blood cells responsible for clotting.

Immune cells in the gut follow an atypical pathway to produce antibodies that provide long-term protection against viruses, according to a new study ...

Discover why some people get swarmed while others escape bites and what really causes that irresistible itchy bump.

New phase 3 data showed that patients with primary immune thrombocytopenia saw improved disease control when ianalumab was added to Promacta (eltrombopag) treatment compared to Promacta alone. Data ...

Egg-based antibody demonstrated significant improvements in poultry livability and feed efficiency across commercial broiler, ...